Huntington's disease: From mutant huntingtin protein to neurotrophic factor therapy

International Journal of Biomedical Science

Volumn 7, Issue 2, 2011, Pages 89-100

  Sari, Youssef ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Mutant huntingtin protein; Neuroprotection; Neurotrophic factors; Neurturin

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM ION; CASPASE 3; CASPASE 6; CELL PROTEIN; CILIARY NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HUNTINGTIN; LENTIVIRUS VECTOR; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NEURTURIN; PROTEIN HAP1; PROTEIN TYROSINE KINASE A; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR TAFII130; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

AMINO ACID TRANSPORT; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARBOXY TERMINAL SEQUENCE; CELL BASED GENE THERAPY; CELL ENCAPSULATION; CELL FUNCTION; CELL NUCLEUS; CELL SURVIVAL; CORPUS STRIATUM; ENDOCYTOSIS; GENE; GENE EXPRESSION; GLIA CELL; GLUTAMATE TRANSPORT; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR TRANSPORT; MITOCHONDRION; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SCNBETA4 GENE; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA;

EID: 79959621517     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. HDCRG HsDCRG. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993 Mar 26; 72 (6): 971-983.
2. McMurray CT. Huntington's disease: new hope for therapeutics. Trends Neurosci. 2001 Nov; 24 (11 Suppl): S32-38.
3. de la Monte SM, Vonsattel JP, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol Exp. Neurol. 1988 Sep; 47 (5): 516-525.
4. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, et al. Neuropathological classification of Huntington's disease. J. Neuropathol Exp. Neurol. 1985 Nov; 44 (6): 559-577.
5. Vonsattel JP, DiFiglia M. Huntington disease. J. Neuropathol Exp. Neurol. 1998 May; 57 (5): 369-384.
6. Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep. 2010 Jan-Feb; 62 (1): 1-14.
7. Han I, You Y, Kordower JH, Brady ST, et al. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 2010 Jun; 113 (5): 1073-1091.
8. Heinsen H, Rub U, Bauer M, Ulmar G, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta. Neuropathol. 1999 Jun; 97 (6): 613-622.
9. Oyanagi K, Takeda S, Takahashi H, Ohama E, et al. A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 1989 Jul; 26 (1): 13-19.
10. Alberch J, Perez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res. 2004; 146: 195-229.
11. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004 Jul 9; 118 (1): 127-138.
12. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends in biochemical sciences. 2003 Aug; 28 (8): 425-433.
13. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001 Jul 20; 293 (5529): 493-498.
14. Zuccato C, Tartari M, Crotti A, Goffredo D, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003 Sep; 35 (1): 76-83.
15. Wang Y, Lin F, Qin ZH. The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. Neurosci Bull. 2010 Apr; 26 (2): 153-162.
16. Davies SW, Turmaine M, Cozens BA, DiFiglia M, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997 Aug 8; 90 (3): 537-548.
17. Dragatsis I, Dietrich P, Zeitlin S. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse. Neurosci. Lett. 2000 Mar 17; 282 (1-2): 37-40.
18. Duyao MP, Auerbach AB, Ryan A, Persichetti F, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995 Jul 21; 269 (5222): 407-10.
19. Gusella JF, MacDonald ME. Huntingtin: a single bait hooks many species. Current opinion in neurobiology. 1998 Jun; 8 (3): 425-30.
20. Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA. 1995 Sep 12; 92 (19): 8710-8714.
21. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995 Jun 2; 81 (5): 811-823.
22. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet. 1995 Oct; 11 (2): 155-163.
23. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. 1999 May; 157 (1): 1-18.
24. Reddy PH, Williams M, Tagle DA. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 1999 Jun; 22 (6): 248-255.
25. Wu LL, Zhou XF. Huntingtin associated protein 1 and its functions. Cell Adh. Migr. 2009 Jan 26; 3 (1).
26. Bao J, Sharp AH, Wagster MV, Becher M, et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. USA. 1996 May 14; 93 (10): 5037-5042.
27. Burke JR, Enghild JJ, Martin ME, Jou YS, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 1996 Mar; 2 (3): 347-350.
28. Kalchman MA, Graham RK, Xia G, Koide HB, et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 1996 Aug 9; 271 (32): 19385-19394.
29. Li XJ, Li SH, Sharp AH, Nucifora FC., et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 1995 Nov 23; 378 (6555): 398-402.
30. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Human molecular genetics. 1997 Mar; 6 (3): 487-495.
31. Shin JY, Fang ZH, Yu ZX, Wang CE, et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. The Journal of cell biology. 2005 Dec 19; 171 (6): 1001-1012.
32. Sack GH. Mitochondrial matters in Huntington disease. J. Bioenerg. Biomembr. 2010 Jun; 42 (3): 189-191.
33. Oliveira JM. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J. Neurochem. 2010 Jul; 114 (1): 1-12.
34. Jin YN, Johnson GV. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 2010 Jun; 42 (3): 199-205.
35. Gu M, Gash MT, Mann VM, Javoy-Agid F, et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996 Mar; 39 (3): 385-389.
36. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 2000 Jan; 47 (1): 80-86.
37. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002 Aug; 5 (8): 731-736.
38. Milakovic T, Quintanilla RA, Johnson GV. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: Functional consequences. J. Biol. Chem. 2006 Sep 13.
39. Gutekunst CA, Li SH, Yi H, Ferrante RJ, et al. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 1998 Oct 1; 18 (19): 7674-7686.
40. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 2006 Feb; 96 (3): 743-757.
41. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiological reviews. 1999 Jul; 79 (3): 763-854.
42. Luthi-Carter R, Strand A, Peters NL, Solano SM, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human molecular genetics. 2000 May 22; 9 (9): 1259-1271.
43. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA. 2005 Feb 15; 102 (7): 2602-2607.
44. Wu J, Tang T, Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci. Lett. 2006 Sep 5.
45. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular and cellular neurosciences. 2004 Mar; 25 (3): 469-479.
46. Behrens PF, Franz P, Woodman B, Lindenberg KS, et al. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 2002 Aug; 125 (Pt 8): 1908-1922.
47. Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiology of disease. 2009 Apr; 34 (1): 78-86.
48. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiology of disease. 2001 Oct; 8 (5): 807-821.
49. Miller BR, Dorner JL, Shou M, Sari Y, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience. 2008 Apr 22; 153 (1): 329-337.
50. Sari Y, Prieto AL, Barton SJ, Miller BR, et al. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J. Biomed. Sci. 2010; 17: 62.
51. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004 Oct 1; 322 (4): 1310-1317.
52. Tang TS, Guo C, Wang H, Chen X, et al. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J. Neurosci. 2009 Feb 4; 29 (5): 1257-1266.
53. Leist M, Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Experimental cell research. 1998 Mar 15; 239 (2): 183-201.
54. Susin SA, Zamzami N, Castedo M, Hirsch T, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. The Journal of experimental medicine. 1996 Oct 1; 184 (4): 1331-1341.
55. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998 Aug 28; 281 (5381): 1312-1316.
56. Graham RK, Deng Y, Slow EJ, Haigh B, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006 Jun 16; 125 (6): 1179-1191.
57. Mende-Mueller LM, Toneff T, Hwang SR, Chesselet MF, et al. Tissuespecific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N-and C-terminal htt fragments in Huntington's disease striatum. J. Neurosci. 2001 Mar 15; 21 (6): 1830-1837.
58. Davies S, Ramsden DB. Huntington's disease. Mol. Pathol. 2001 Dec; 54 (6): 409-413.
59. Ona VO, Li M, Vonsattel JP, Andrews LJ, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999 May 20; 399 (6733): 263-267.
60. Wellington CL, Leavitt BR, Hayden MR. Huntington disease: new insights on the role of huntingtin cleavage. J. Neural. Transm. Suppl. 2000 (58): 1-17.
61. Pattison LR, Kotter MR, Fraga D, Bonelli RM. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J. Neurol. 2006 Sep 22.
62. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, et al. Huntingtin inhibits caspase-3 activation. The EMBO journal. 2006 Dec 13; 25 (24): 5896-5906.
63. Chopra VS, Metzler M, Rasper DM, Engqvist-Goldstein AE, et al. HIP12 is a non-proapoptotic member of a gene family including HIP1, an interacting protein with huntingtin. Mamm Genome. 2000 Nov; 11 (11): 1006-1015.
64. Kalchman MA, Koide HB, McCutcheon K, Graham RK, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membraneassociated huntingtin in the brain. Nat. Genet. 1997 May; 16 (1): 44-53.
65. Modregger J, DiProspero NA, Charles V, Tagle DA, et al. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Human molecular genetics. 2002 Oct 1; 11 (21): 2547-2558.
66. Seki N, Muramatsu M, Sugano S, Suzuki Y, et al. Cloning, expression analysis, and chromosomal localization of HIP1R, an isolog of huntingtin interacting protein (HIP1). Journal of human genetics. 1998; 43 (4): 268-271.
67. Singaraja RR, Hadano S, Metzler M, Givan S, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human molecular genetics. 2002 Nov 1; 11 (23): 2815-2828.
68. Sittler A, Walter S, Wedemeyer N, Hasenbank R, et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Molecular cell. 1998 Oct; 2 (4): 427-436.
69. Block-Galarza J, Chase KO, Sapp E, Vaughn KT, et al. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport. 1997 Jul 7; 8 (9-10): 2247-2251.
70. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO reports. 2004 Oct; 5 (10): 958-963.
71. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003 May; 19 (5): 233-238.
72. Dunah AW, Jeong H, Griffin A, Kim YM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 2002 Jun 21; 296 (5576): 2238-2243.
73. Kegel KB, Meloni AR, Yi Y, Kim YJ, et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 2002 Mar 1; 277 (9): 7466-7476.
74. McCampbell A, Taylor JP, Taye AA, Robitschek J, et al. CREB-binding protein sequestration by expanded polyglutamine. Human molecular genetics. 2000 Sep 1; 9 (14): 2197-2202.
75. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA. 2000 Jun 6; 97 (12): 6763-6768.
76. Li SH, Cheng AL, Zhou H, Lam S, et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Molecular and cellular biology. 2002 Mar; 22 (5): 1277-1287.
77. Pugh BF, Tjian R. Mechanism of transcriptional activation by Sp1: evidence for coactivators. Cell. 1990 Jun 29; 61 (7): 1187-1197.
78. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 2002 May; 31 (1): 47-54.
79. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000; 97 (3): 505-519.
80. Shimohata T, Nakajima T, Yamada M, Uchida C, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREBdependent transcription. Nat. Genet. 2000 Sep; 26 (1): 29-36.
81. Cornett J, Smith L, Friedman M, Shin JY, et al. Context-dependent dysregulation of transcription by mutant huntingtin. J. Biol. Chem. 2006 Nov 24; 281 (47): 36198-36204.
82. Holbert S, Denghien I, Kiechle T, Rosenblatt A, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl. Acad. Sci. USA. 2001 Feb 13; 98 (4): 1811-1816.
83. Boutell JM, Thomas P, Neal JW, Weston VJ, et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Human molecular genetics. 1999 Sep; 8 (9): 1647-1655.
84. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 1981 Dec; 10 (6): 499-505.
85. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev. 1998 Jun; 27 (1): 1-39.
86. Kruttgen A, Saxena S, Evangelopoulos ME, Weis J. Neurotrophins and neurodegenerative diseases: receptors stuck in traffic? J. Neuropathol. Exp. Neurol. 2003 Apr; 62 (4): 340-350.
87. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001 Jan; 63 (1): 71-124.
88. Chao MV. Neurotrophin receptors: a window into neuronal differentiation. Neuron. 1992 Oct; 9 (4): 583-593.
89. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001; 24: 677-736.
90. Lai KO, Fu WY, Ip FC, Ip NY. Cloning and expression of a novel neurotrophin, NT-7, from carp. Molecular and cellular neurosciences. 1998 May; 11 (1-2): 64-76.
91. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996; 19: 289-317.
92. Nilsson AS, Fainzilber M, Falck P, Ibanez CF. Neurotrophin-7: a novel member of the neurotrophin family from the zebrafish. FEBS Lett. 1998 Mar 13; 424 (3): 285-290.
93. Alderson RF, Alterman AL, Barde YA, Lindsay RM. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron. 1990 Sep; 5 (3): 297-306.
94. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu. Rev. Neurosci. 1999; 22: 295-318.
95. Nonomura T, Hatanaka H. Neurotrophic effect of brain-derived neurotrophic factor on basal forebrain cholinergic neurons in culture from postnatal rats. Neurosci Res. 1992 Aug; 14 (3): 226-233.
96. Glass DJ, Yancopoulos GD. The neurotrophins and their receptors. Trends Cell Biol. 1993 Aug; 3 (8): 262-268.
97. Chao MV, Hempstead BL. P75 and Trk: a two-receptor system. Trends Neurosci. 1995 Jul; 18 (7): 321-326.
98. Lin LF, Doherty DH, Lile JD, Bektesh S, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993 May 21; 260 (5111): 1130-1132.
99. Cacalano G, Farinas I, Wang LC, Hagler K, et al. GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron. 1998 Jul; 21 (1): 53-62.
100. Heuckeroth RO, Enomoto H, Grider JR, Golden JP, et al. Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons. Neuron. 1999 Feb; 22 (2): 253-263.
101. Klein RD, Sherman D, Ho WH, Stone D, et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature. 1997 Jun 12; 387 (6634): 717-721.
102. Adler R, Landa KB, Manthorpe M, Varon S. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science. 1979 Jun 29; 204 (4400): 1434-1436.
103. Manthorpe M, Davis GE, Varon S. Purified proteins acting on cultured chick embryo ciliary ganglion neurons. Federation proceedings. 1985 Sep; 44 (12): 2753-2759.
104. Davis S, Aldrich TH, Ip NY, Stahl N, et al. Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses. Science. 1993 Mar 19; 259 (5102): 1736-1739.
105. Davis S, Yancopoulos GD. The molecular biology of the CNTF receptor. Current opinion in cell biology. 1993 Apr; 5 (2): 281-285.
106. Altar CA, Cai N, Bliven T, Juhasz M, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997 Oct 23; 389 (6653): 856-860.
107. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004 Apr 28; 24 (17): 4250-4258.
108. Lynch G, Kramar EA, Rex CS, Jia Y, et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J. Neurosci. 2007 Apr 18; 27 (16): 4424-4434.
109. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998 Oct 2; 95 (1): 55-66.
110. Pineda JR, Canals JM, Bosch M, Adell A, et al. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J. Neurochem. 2005 Jun; 93 (5): 1057-1068.
111. Ferrer I, Goutan E, Marin C, Rey MJ, et al. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000 Jun 2; 866 (1-2): 257-261.
112. Duan W, Guo Z, Jiang H, Ware M, et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. USA. 2003 Mar 4; 100 (5): 2911-2916.
113. Gines S, Seong IS, Fossale E, Ivanova E, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Human molecular genetics. 2003 Mar 1; 12 (5): 497-508.
114. Hermel E, Gafni J, Propp SS, Leavitt BR, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell death and differentiation. 2004 Apr; 11 (4): 424-438.
115. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Human molecular genetics. 2002 Aug 15; 11 (17): 1911-1926.
116. Spires TL, Grote HE, Varshney NK, Cordery PM, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 2004 Mar 3; 24 (9): 2270-2276.
117. Zuccato C, Liber D, Ramos C, Tarditi A, et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res. 2005 Aug; 52 (2): 133-139.
118. Zuccato C, Tartari M, Goffredo D, Cattaneo E, et al. From target identification to drug screening assays for neurodegenerative diseases. Pharmacol Res. 2005 Sep; 52 (3): 245-251.
119. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, et al. Brainderived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004 Sep 1; 24 (35): 7727-7739.
120. Wu LL, Fan Y, Li S, Li XJ, et al. Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J. Biol. Chem. 2010 Feb 19; 285 (8): 5614-5623.
121. Pardo R, Molina-Calavita M, Poizat G, Keryer G, et al. Paris-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain. 2010; 3: 17.
122. Gines S, Bosch M, Marco S, Gavalda N, et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci. 2006 Feb; 23 (3): 649-658.
123. Gines S, Paoletti P, Alberch J. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J. Biol. Chem. 2010 Jul 9; 285 (28): 21537-21548.
124. Deogracias R, Espliguero G, Iglesias T, Rodriguez-Pena A. Expression of the neurotrophin receptor trkB is regulated by the cAMP/ CREB pathway in neurons. Molecular and cellular neurosciences. 2004 Jul; 26 (3): 470-480.
125. Sugars KL, Brown R, Cook LJ, Swartz J, et al. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 2004 Feb 6; 279 (6): 4988-4999.
126. Wyttenbach A, Swartz J, Kita H, Thykjaer T, et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Human molecular genetics. 2001 Aug 15; 10 (17): 1829-1845.
127. Gharami K, Xie Y, An JJ, Tonegawa S, et al. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008 Apr; 105 (2): 369-379.
128. Bemelmans AP, Horellou P, Pradier L, Brunet I, et al. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999 Dec 10; 10 (18): 2987-2997.
129. Kells AP, Fong DM, Dragunow M, During MJ, et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther. 2004 May; 9 (5): 682-688.
130. Martinez-Serrano A, Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci. 1996 Aug 1; 16 (15): 4604-4616.
131. Perez-Navarro E, Alberch J, Neveu I, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience. 1999; 91 (4): 1257-1264.
132. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, et al. Brainderived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 2000 Nov; 75 (5): 2190-2199.
133. Ryu JK, Kim J, Cho SJ, Hatori K, et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiology of disease. 2004 Jun; 16 (1): 68-77.
134. Haque NS, Isacson O. Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell transplantation. 2000 Sep-Oct; 9 (5): 623-627.
135. Bjugstad KB, Zawada WM, Goodman S, Free CR. IGF-1 and bFGF reduce glutaric acid and 3-hydroxyglutaric acid toxicity in striatal cultures. Journal of inherited metabolic disease. 2001 Nov; 24 (6): 631-647.
136. Palmer TD, Ray J, Gage FH. FGF-2-responsive neuronal progenitors reside in proliferative and quiescent regions of the adult rodent brain. Molecular and cellular neurosciences. 1995 Oct; 6 (5): 474-486.
137. Zhou D, DiFiglia M. Basic fibroblast growth factor enhances the growth of postnatal neostriatal GABAergic neurons in vitro. Exp. Neurol. 1993 Aug; 122 (2): 171-188.
138. Jin K, LaFevre-Bernt M, Sun Y, Chen S, et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA. 2005 Dec 13; 102 (50): 18189-18194.
139. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, et al. Glial cell linederived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 1994 Nov 21; 182 (1): 107-111.
140. Kim BT, Rao VL, Sailor KA, Bowen KK, et al. Protective effects of glial cell line-derived neurotrophic factor on hippocampal neurons after traumatic brain injury in rats. J. Neurosurg. 2001 Oct; 95 (4): 674-679.
141. Perez-Navarro E, Arenas E, Reiriz J, Calvo N, et al. Glial cell linederived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience. 1996 Nov; 75 (2): 345-352.
142. Watabe K, Ohashi T, Sakamoto T, Kawazoe Y, et al. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J. Neurosci Res. 2000 May 15; 60 (4): 511-519.
143. Alberch J, Perez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain research bulletin. 2002 Apr; 57 (6): 817-822.
144. Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp. Neurol. 2010 Jul; 224 (1): 155-162.
145. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA. 2006 Jun 13; 103 (24): 9345-9350.
146. Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp. Neurol. 2005 May; 193 (1): 65-74.
147. Gratacos E, Perez-Navarro E, Tolosa E, Arenas E, et al. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem. 2001 Sep; 78 (6): 1287-1296.
148. Rosenblad C, Kirik D, Devaux B, Moffat B, et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 1999 May; 11 (5): 1554-1566.
149. Ramaswamy S, McBride JL, Herzog CD, Brandon E, et al. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of disease. 2007 May; 26 (2): 375-384.
150. Lebherz C, Auricchio A, Maguire AM, Rivera VM, et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther. 2005 Feb; 16 (2): 178-186.
151. Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, et al. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiology of disease. 2009 Apr; 34 (1): 40-50.
152. Perez-Navarro E, Akerud P, Marco S, Canals JM, et al. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience. 2000; 98 (1): 89-96.
153. Albin RL, Reiner A, Anderson KD, Dure LST, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992 Apr; 31 (4): 425-430.
154. Reiner A, Albin RL, Anderson KD, D'Amato CJ, et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA. 1988 Aug; 85 (15): 5733-5737.
155. Marco S, Perez-Navarro E, Tolosa E, Arenas E, et al. Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease. J. Neurobiol. 2002 Mar; 50 (4): 323-332.
156. Linker RA, Maurer M, Gaupp S, Martini R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 2002 Jun; 8 (6): 620-624.
157. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, et al. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J. Neurosci. 2002 Nov 1; 22 (21): 9221-9217.
158. Anderson KD, Panayotatos N, Corcoran TL, Lindsay RM, et al. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA. 1996 Jul 9; 93 (14): 7346-7351.
159. Emerich DF, Lindner MD, Winn SR, Chen EY, et al. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 1996 Aug 15; 16 (16): 5168-5181.
160. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther. 2004 Oct; 15 (10): 968-975.
161. Emerich DF, Thanos CG. Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. Current gene therapy. 2006 Feb; 6 (1): 147-159.
162. Emerich DF, Winn SR. Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum. Cell transplantation. 2004; 13 (3): 253-259.
163. Emerich DF, Winn SR, Hantraye PM, Peschanski M, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 1997 Mar 27; 386 (6623): 395-399.